Norepinephrine uptake mechanisms in cardiovascular disease deserve our attention

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 4, 2011, Pages 406-408

  Schroeder, Christoph ^a   Jordan, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPAMINE F 18; CARVEDILOL; CIMETIDINE; CORTICOSTEROID; IMIPRAMINE; NORADRENALIN; OCTAMER TRANSCRIPTION FACTOR 4; SIBUTRAMINE; VERAPAMIL;

AMINE TRANSPORT; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; ESSENTIAL HYPERTENSION; GENE MUTATION; HEART ARRHYTHMIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MOLECULAR MECHANICS; NONHUMAN; NOTE; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL;

EID: 85027956385     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0B013E31822EAE22     Document Type: Note

References (38)

1. Grundemann D, Schechinger B, Rappold GA, et al. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1:349-351.
2. Solbach TF, Grube M, Fromm MF, et al. Organic cation transporter-3: expression in failing and nonfailing human heart and functional characterization. J Cardiovasc Pharmacol. 2011 .
3. Shannon JR, Flattem N, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine transporter deficiency. N Engl J Med. 2000;342:541-549. (Pubitemid 30117894)
4. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci. 2003;23:4470-4478. (Pubitemid 36706177)
5. Lambert E, Eikelis N, Esler M, et al. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 2008;1:103-109.
6. Schroeder C, Tank J, Boschmann M, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002;105:347-353. (Pubitemid 34106184)
7. Birkenfeld AL, Schroeder C, Boschmann M, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002; 106:2459-2465. (Pubitemid 35278802)
8. Jordan J, Lipp A, Tank J, et al. Catechol-o-methyltransferase and blood pressure in humans. Circulation. 2002;106:460-465. (Pubitemid 34803691)
9. Chang PC, van der Krogt JA, Vermeij P, et al. Norepinephrine removal and release in the forearm of healthy subjects. Hypertension. 1986;8:801-809. (Pubitemid 16049586)
10. Gasser PJ, Orchinik M, Raju I, et al. Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol. 2009;512:529-555.
11. Cui M, Aras R, Christian WV, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A. 2009;106:8043-8048.
12. Eisenhofer G, Saigusa T, Esler MD, et al. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol. 1991;260(pt 2):R824-R832.
13. Esler MD, Wallin G, Dorward PK, et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol. 1991;260(pt 2):R817-R823.
14. Tank J, Schroeder C, Diedrich A, et al. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003;107:2949-2954. (Pubitemid 36736638)
15. Rumantir MS, Kaye DM, Jennings GL, et al. Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension. 2000;36:824-829.
16. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension. 2004;43:169-175. (Pubitemid 38174169)
17. McCance AJ, Thompson PA, Forfar JC. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J. 1993;14:751-757. (Pubitemid 23198890)
18. Kume T, Kawamoto T, Okura H, et al. Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction. Circ J. 2008;72:106-108. (Pubitemid 351413336)
19. Adamopoulos S, Kemp GJ, Thompson CH, et al. The time course of haemodynamic, autonomic and skeletal muscle metabolic abnormalities following first extensive myocardial infarction in man. J Mol Cell Cardiol. 1999;31:1913-1926. (Pubitemid 29458708)
20. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986; 73:615-621. (Pubitemid 16081418)
21. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
23. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet. 1999;353:2001-2007.
24. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-827. (Pubitemid 11017550)
25. Simoes MV, Barthel P, Matsunari I, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551-557. (Pubitemid 38478547)
26. Schomig E, Schonfeld CL. Extraneuronal noradrenaline transport (uptake2) in a human cell line (Caki-1 cells). Naunyn Schmiedebergs Arch Pharmacol. 1990;341:404-410. (Pubitemid 20154550)
27. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12: 1252-1258.
28. Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213-1218. (Pubitemid 47492905)
29. Kuramoto Y, Yamada T, Tamaki S, et al. Usefulness of cardiac iodine- 123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle heart failure model in patients with chronic heart failure. Am J Cardiol. 2011;107:1185-1190.
30. De RS, Beauloye C, De B, et al. Tako-tsubo syndrome following nortriptyline overdose. Clin Toxicol (Phila). 2008;46:475-478. (Pubitemid 351878653)
31. Bohm M, La RK, Schwinger RH, et al. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25:146-153.
32. Beau SL, Saffitz JE. Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol. 1994;23:579-585. (Pubitemid 24074932)
33. Munch G, Rosport K, Bultmann A, et al. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res. 2005;97:928-936. (Pubitemid 41552679)
34. Zwart R, Verhaagh S, Buitelaar M, et al. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol. 2001;21:4188-4196. (Pubitemid 32565301)
35. Aoyama N, Takahashi N, Kitaichi K, et al. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res. 2006;30:1644-1649. (Pubitemid 44465604)
36. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-917.
37. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136:829-836. (Pubitemid 34836857)
38. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.